Novo Nordisk CEO: Wegovy pill has exceeded expectations
FROM THE WIRE · FINANCE.YAHOO.COM
The Wegovy pill looks like a win for Novo Nordisk (NVO) after what some on Wall Street saw as a slower-than-expected consumer uptake. "The Wegovy pill has exceeded our expectations," Novo Nordisk CEO Mike Doustdar said on Sozzi Unleashed. Doustdar said the pill will be available…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishQuarterly sales growth and a second full-year outlook raise in three months support the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third quarter sales rose 4% to DKK 79.2 billion.
- 02Sales of the new Wegovy pill reached DKK 5.4 billion.
- 03The company raised its full-year outlook, with sales and adjusted operating profit rising as much as 2%.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets